Dernière mise à jour : 29 septembre 2015
Détails
FichiersGeneric Name:
Sorafenib
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Fabricant:
Bayer Inc.
Brand Name:
Nexavar
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0049-000
Strength:
200 mg tablet
Tumour Type:
Endocrine
Indications:
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Funding Request:
Treatment of patients with locally advanced or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine
Date NOC Issued:
Sponsor:
Bayer Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et accordée
Stakeholder Input Deadline ‡:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Ne pas rembourser
Clarification:
Due to the number of items for deliberation, the pERC meeting was conducted over two days. Unable to reach quorum for either day around the target reconsideration meeting date of June 18, 2015, pERC held deliberations for all reconsideration items, including sorafenib, on July 2, 2015.
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 29 septembre 2015